Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence. Subscribe to TipRanks' Smart Investor Picks and see our data in action through our ...

BOSTON - Praxis Precision Medicines, Inc. (NASDAQ:PRAX) announced Tuesday it will immediately convert its EMBRAVE3 registrational study for elsunersen in SCN2A developmental and epileptic ...

Praxis Precision Medicines, Inc. (NASDAQ:PRAX) is among the hidden multibagger stocks to invest in. It reported positive results from the registrational cohort of the EMBOLD study on December 4. This ...

Praxis Precision Medicines (PRAX) just hit a double inflection point, with its EMBOLD trial for relutrigine stopped early for efficacy and a successful pre-NDA meeting for ulixacaltamide setting up a ...

Praxis Precision Medicines, Inc. (PRAX) stock is soaring in trading today, up 35% at time of writing, with shares reaching a value of $260, their highest value since the beginning of 2022. Current ...

Having already claimed a win for the phase 2 study of its seizure drug, Praxis Precision Medicines is hoping fresh efficacy data will form the backbone of an approval application for the sodium ...

"SCN2A and SCN8A DEEs are devastating conditions with extremely high mortality due to the debilitating seizure burden they impose on patients, and there are currently no approved treatment options.

Investing.com -- Praxis Precision Medicines (NASDAQ:PRAX) stock surged 25% after the company announced its EMBOLD study evaluating relutrigine was stopped early due to positive efficacy results. The ...

BOSTON, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for ...

Looking for a gift to keep kids busy over winter break? Get them a National Geographic science kit. A ton are on sale at Amazon right now, and most are 30 percent off. I think the Super Gross ...

Computer Weekly Buyer’s Guides map the IT buying cycle of our readership onto relevant editorial that will inform and educate readers and help them in making the right buying decision. On a three-week ...

Culper Research report argues that the data underpinning its essential tremor program cannot withstand regulatory scrutiny. According to the short report, Praxis engineered its October 2025 results ...